Clinical

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Articles

Now called Camzyos, the therapy is first-in-class and treats the underlying cause of the disease. It is expected to be available next week.

FDA Approves Mavacamten for Hypertrophic Cardiomyopathy

The recall of Accuretic and generics distributed by Greenstone is a result of the presence of a cancer-causing agent.

Pfizer Recalls Blood Pressure Drug Accuretic

But there is no significant difference in rate of hospitalization for major bleeding when Eliquis is compared with Xarelto or warfarin.

Study: Eliquis Can Lower Hospitalizations after VTE


Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.



Medicare Could Save with Use of Generic Cardiovascular Meds

The study found that nearly half of Americans diagnosed with high blood pressure do not have it sufficiently controlled.

 Study Finds Patients with Hypertension Take Drugs that Raise Blood Pressure 

Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.

Study: Generic Statins Led to Significant Cost Savings

Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

FDA Approves Treatment for Rare Blood Disease

If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.

FDA Accepts Supplemental NDA for Jardiance 

Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.

Prime Therapeutics Reviews Treatment Costs for Rare Blood Disease

Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group
